Merck & Co Inc (FRA:6MK)
€ 92.9 -0.2 (-0.21%) Market Cap: 236.96 Bil Enterprise Value: 261.27 Bil PE Ratio: 21.36 PB Ratio: 5.93 GF Score: 78/100

Merck & Co Inc at TD Cowen Health Care Conference Transcript

Mar 05, 2024 / 06:30PM GMT
Release Date Price: €114 (+0.18%)
Stephen Michael Scala
TD Cowen, Research Division - MD & Senior Research Analyst

We are delighted to have Merck here at Cowen's 44th Annual Healthcare Conference. Representing the company, Joe Romanelli, who is President of Human Health International. Also joining us here on stage, Peter Dannenbaum, who is Head of Investor Relations.

So thank you so much for making the effort to be with us today. Lots to talk about. Obviously, OUS Merck is a big business, diverse business, lots going on. So we want to dig into all these topics in the next 30 minutes or so.

Questions & Answers

Stephen Michael Scala
TD Cowen, Research Division - MD & Senior Research Analyst

Let me start out by asking about one of Merck's biggest successes and that is GARDASIL. And Merck has this ambition that it's going to achieve roughly $11 billion in 2030. But we, in our models, show the product pretty much achieving that just in international and then, of course, the U.S. So tell me why $11 billion is the cap and why it can't be a whole lot larger and maybe that

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot